Effect of Long-term Fenofibrate Therapy on Serum Creatinine and Its Reversibility in Hypertriglyceridemic Patients with Hypertension

Gyu Tae Park; Moonki Jung; Young Kim; Iksung Cho; Hoyoun Won; Seung Yong Shin; Wang-Soo Lee; Kwang Je Lee; Sang-Wook Kim; Tae Ho Kim; 김치정

doi:https://doi.org/10.12997/jla.2017.6.2.89

추천

검색

자료유형: 학술저널

저자정보: Gyu Tae Park (College of Medicine Chung-Ang University) Moonki Jung (College of Medicine Chung-Ang University) Young Kim (College of Medicine Chung-Ang University) Iksung Cho (College of Medicine Chung-Ang University) Hoyoun Won (College of Medicine Chung-Ang University) Seung Yong Shin (College of Medicine Chung-Ang University) Wang-Soo Lee (College of Medicine Chung-Ang University) Kwang Je Lee (College of Medicine Chung-Ang University) Sang-Wook Kim (College of Medicine Chung-Ang University) Tae Ho Kim (College of Medicine Chung-Ang University) 김치정 (중앙대학교)

저널정보: 한국지질동맥경화학회(구 한국지질학회) 지질·동맥경화학회지 지질·동맥경화학회지 제6권 제2호

발행연도: 2017.12

수록면: 89 - 96 (8page)

DOI: https://doi.org/10.12997/jla.2017.6.2.89

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: Previous studies have shown that fenofibrate therapy increases serum creatinine level and that there is a returnof serum creatinine to baseline level after the discontinuation of the drug. We evaluated the effect of long-term fenofibratetherapy on creatinine levels and its reversibility in patients with hypertension and hypertriglyceridemia. Methods: This retrospective study enrolled 54 hypertensive and hypertriglyceridemic patients taking fenofibrate for 3-6years (Fenofibrate group) and 30 control patients with similar age, sex, follow-up duration, and creatinine levels (Controlgroup). In 23 patients taking fenofibrate with low triglyceride level and/or with high creatinine levels, fenofibrate was discontinued,and creatinine levels were measured after 2 months. Results: Creatinine levels increased in both the fenofibrate group (from 0.91±0.18 mg/dL to 1.09±0.23 mg/dL, p<0.001)and the control group (from 0.94±0.16 mg/dL to 0.98±0.16 mg/dL, p=0.04) compared to baseline. However, the elevationwas more pronounced in the fenofibrate group than in the control group (21.1±15.4% vs. 4.5±11.3%, p<0.001). Thediscontinuation of fenofibrate lowered creatinine levels (from 1.39±0.32 mg/dL to 1.15±0.24 mg/dL, p<0.001) whichwere still higher than pre-treatment levels (p=0.013). Conclusion: Long-term fenofibrate therapy significantly increased creatinine levels in hypertensive and hypertriglyceridemicpatients. The effect of fenofibrate on creatinine level was partially reversible. This finding suggests that follow-up creatininelevel is necessary with fenofibrate therapy. (J Lipid Atheroscler 2017 December;6(2):89-96)

#Fenofibrate #Creatinine #Hypertension #Hypertriglyceridemia #Nephrotoxicity

참고문헌 (22)

참고문헌 신청

Shah A / 2010 / The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans / Atherosclerosis 210:35~40

Kim CJ / 2013 / Management of hypertriglyceridemia for prevention of cardiovascular diseases / J Lipid Atheroscler 2:53~60

Davidson MH / 2007 / Safety considerations with fibrate therapy / Am J Cardiol 99:3C~18C

Lageder H / 1980 / Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia / Wien Klin Wochenschr 92:95~101

Dick TB / 1981 / Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia / Curr Med Res Opin 7:489~502

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

박규태

소속기관 부산대학교

주요연구분야 공학 > 전기전자공학 > 제어계측공학 공학 > 컴퓨터학

논문수 31 이용수 547

Moonki Jung